Orion Pharma Limited (DSE: ORIONPHARM)
Bangladesh
· Delayed Price · Currency is BDT 42.60
-0.70 (-1.62%)
At close: Nov 14, 2024
Orion Pharma Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | Jun '19 Jun 30, 2019 | 2018 - 2014 |
| Revenue | 11,496 | 13,927 | 9,662 | 10,833 | 7,648 | 8,705 | Upgrade
|
| Revenue Growth (YoY) | -31.54% | 44.14% | -10.81% | 41.64% | -12.15% | -16.48% | Upgrade
|
| Cost of Revenue | 9,329 | 11,652 | 7,693 | 8,198 | 5,075 | 6,164 | Upgrade
|
| Gross Profit | 2,168 | 2,275 | 1,969 | 2,635 | 2,573 | 2,541 | Upgrade
|
| Selling, General & Admin | 1,504 | 1,282 | 1,294 | 1,138 | 1,026 | 957.45 | Upgrade
|
| Other Operating Expenses | -22.87 | -22.87 | -14.2 | -41.7 | -5.44 | -1.57 | Upgrade
|
| Operating Expenses | 1,482 | 1,259 | 1,279 | 1,096 | 1,021 | 955.87 | Upgrade
|
| Operating Income | 686.03 | 1,016 | 689.32 | 1,538 | 1,552 | 1,585 | Upgrade
|
| Interest Expense | -149.24 | -148.29 | -173.23 | -223.43 | -717.01 | -561.51 | Upgrade
|
| Interest & Investment Income | 3.55 | 3.31 | 638.31 | 3.19 | 33.79 | 27.2 | Upgrade
|
| Earnings From Equity Investments | 9.3 | 9.13 | 9.3 | 6.07 | 6.47 | 8.72 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.89 | 0.89 | 0.62 | 1.23 | 1.71 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 13.61 | -39.78 | -100.94 | -131.51 | -75.22 | -16.11 | Upgrade
|
| EBT Excluding Unusual Items | 564.14 | 841.09 | 1,063 | 1,194 | 801.85 | 1,044 | Upgrade
|
| Gain (Loss) on Sale of Investments | -1.08 | 0.21 | 0.08 | -5.93 | -0.05 | -7.09 | Upgrade
|
| Pretax Income | 563.71 | 841.3 | 1,063 | 1,193 | 802 | 1,037 | Upgrade
|
| Income Tax Expense | 109.6 | 147.07 | 172.71 | 68.51 | 64.95 | 65.45 | Upgrade
|
| Earnings From Continuing Operations | 454.12 | 694.23 | 890.75 | 1,125 | 737.05 | 971.58 | Upgrade
|
| Minority Interest in Earnings | 1.34 | -53.29 | -44.67 | -185.68 | -71.36 | -89.23 | Upgrade
|
| Net Income | 455.46 | 640.94 | 846.08 | 939.06 | 665.69 | 882.35 | Upgrade
|
| Net Income to Common | 455.46 | 640.94 | 846.08 | 939.06 | 665.69 | 882.35 | Upgrade
|
| Net Income Growth | -34.90% | -24.25% | -9.90% | 41.07% | -24.56% | 10.05% | Upgrade
|
| Shares Outstanding (Basic) | 234 | 234 | 234 | 234 | 234 | 234 | Upgrade
|
| Shares Outstanding (Diluted) | 234 | 234 | 234 | 234 | 234 | 234 | Upgrade
|
| EPS (Basic) | 1.95 | 2.74 | 3.62 | 4.01 | 2.84 | 3.77 | Upgrade
|
| EPS (Diluted) | 1.95 | 2.74 | 3.62 | 4.01 | 2.84 | 3.77 | Upgrade
|
| EPS Growth | -34.90% | -24.25% | -9.90% | 41.07% | -24.56% | 10.05% | Upgrade
|
| Free Cash Flow | -1,221 | -1,366 | -1,505 | -1,685 | 338.88 | 100.09 | Upgrade
|
| Free Cash Flow Per Share | -5.22 | -5.84 | -6.43 | -7.20 | 1.45 | 0.43 | Upgrade
|
| Dividend Per Share | 1.000 | 1.000 | 1.000 | 1.200 | 1.000 | 1.500 | Upgrade
|
| Dividend Growth | 0% | 0% | -16.67% | 20.00% | -33.33% | 0% | Upgrade
|
| Gross Margin | 18.85% | 16.33% | 20.38% | 24.32% | 33.64% | 29.19% | Upgrade
|
| Operating Margin | 5.97% | 7.29% | 7.13% | 14.20% | 20.30% | 18.21% | Upgrade
|
| Profit Margin | 3.96% | 4.60% | 8.76% | 8.67% | 8.70% | 10.14% | Upgrade
|
| Free Cash Flow Margin | -10.62% | -9.81% | -15.58% | -15.56% | 4.43% | 1.15% | Upgrade
|
| EBITDA | 1,180 | 1,597 | 1,162 | 2,529 | 2,461 | 2,407 | Upgrade
|
| EBITDA Margin | 10.26% | 11.47% | 12.03% | 23.34% | 32.19% | 27.65% | Upgrade
|
| D&A For EBITDA | 493.78 | 580.89 | 472.83 | 990.2 | 909.36 | 822.06 | Upgrade
|
| EBIT | 686.03 | 1,016 | 689.32 | 1,538 | 1,552 | 1,585 | Upgrade
|
| EBIT Margin | 5.97% | 7.29% | 7.13% | 14.20% | 20.30% | 18.21% | Upgrade
|
| Effective Tax Rate | 19.44% | 17.48% | 16.24% | 5.74% | 8.10% | 6.31% | Upgrade
|
| Advertising Expenses | - | 20.53 | 19.65 | 21.74 | 26.41 | 33.68 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.